Latest Conference Articles

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

The algorithm identified PPL-HMA in 20% of eyes and was associated with a 2-3 fold increased risk of DR progression, development of PDR and receipt of intravitreal injections over 4 years.

The deep learning algorithm was tested on 71,000 images, and offers the potential to significantly increase the speed at which DR can be identified.

Clinical and biochemical assessments of LPL FCS and non-LPL FCS genes.

FCS community highlights clinical presentation and lifestyle.

Eyes that received only anti-VEGF experienced significantly worse visual acuity from initial visit to final visit.

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.

Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle patients with PDR.

Montes' team found benefits in motor function, walking ability, and fatigue in patients to undergo nusinersen (Spinraza) for spinal muscular atrophy.

The Global Head of Neurodegeneration for Genentech talks about the progress of 2 promising monoclonal antibodies.

Treatment with volanesorsen shows efficacy in patients with FCS.

The vice president of Development Sciences for Biogen shared developments to come of the international MS PATHS collaboration.

Results from a questionnaire show that individuals living with FCS prove that communication among people in similar situations can improve a patient’s quality of life.

At the NLA Scientific Sessions in Las Vegas this morning, Akcea Therapeutics, presented a poster with data from the largest burden of illness study in patients with FCS to date.

Children receiving AVXS-101 have shown such improvement that researchers are calling for an update to the CHOP-INTEND scale used to track their progress.

Patients from 2 demographically-different studies switching from interferon therapy to Aubagio reported similar improvements.

The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

The director of the Sports Neurology Program at Norton Healthcare and head of the NCAA Headache Task Force discussed trends in his popularizing field.

Patients who had previously failed ≥2 preventative migraine treatments were effectively treated with galcanezumab, especially when compared to placebo.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Lead author Alexander D. Rae-Grant, MD, explains the measures taken to ensure the panel got their 16-year multiple sclerosis recommendations update right.

Researchers found that 100U of incobotulinumtoxinA significantly reduced unstimulated salivary flow rate during the 16-week trial and through the 48-week extension.

Already tasked with a burdensome regimen of therapy for nerve damage, some patients may just be looking for simpler relief.

The American Academy of Neurology has issued 30 recommendations for clinicians regarding disease-modifying therapies for multiple sclerosis.

The investigative therapy for SMA reported various efficacy results in a phase 3 extension trial.

Among patients with MS who began ocrelizumab treatment in the open-label extension, MRI lesion activity was almost completely suppressed.

A new study finding that 50% of low income Latino patients with MS suffer from depression is coupled with recent reports on their exclusion from clinical research.